A recent individual patient data analysis showed that I-PET positivity using DS criteria at I-PET3 and I-PET4 was almost identical (21.7 vs 21.2%) [8], implying that the I-PET-positivity rate for MYC- DLBCL patients would be similar after three cycles of treatment. Here, MYC is linked to diffuse large B-cell lymphoma.